Optimized an early-phase oncology spinout’s IND-enabling workflow, achieving a 40% reduction in time-to-submission and enhancing FDA alignment through a biomarker-driven study design.
Developed a dual-AAV preclinical plan and biomarker roadmap that facilitated the smooth IND preparation for a gene therapy startup.
Transformed exploratory mouse model data into a GLP-compliant regulatory study package that was adopted by a collaborating CRO.
From discovery to IND, avoid these 7 common mistakes in early-stage oncology and gene therapy programs. If you mention our ‘IND guide’ when you reach out, we’ll provide you with a live walkthrough of the essential checklist.
We collaborate with accelerators, incubators, and investor groups to offer workshops and strategy sessions focused on IND readiness. To discuss a session tailored for your portfolio or program, please reach out through the contact form.
Coming soon: CellGene IND Navigator™ - a proprietary framework designed to assess and accelerate IND readiness through key preclinical and regulatory milestones.
Copyright © 2026 CellGene Nexus - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.